Entries |
Document | Title | Date |
20080206349 | Spray Dried Compositions - The invention provides a method comprising the steps of: (i) providing an emulsion of: a) an aqueous solvent, such as water, b) a carrier material dispersible or soluble in (a), said carrier material being solid at ambient temperature, and preferably being a polymer and inorganic salt or a surfactant, c) a volatile second liquid phase (for example, chloroform) which is not miscible with (a), and d) a material which is dispersible or soluble in (c) but not in (a), and, (ii) Drying the emulsion at above ambient temperature (preferably by spray drying) to simultaneously remove (a) and (c) and thereby obtain the material (b) in solid form with (d) dispersed therein. | 08-28-2008 |
20080206350 | PELLETS HAVING A GASTRIC JUICE-RESISTANT ACTIVE COMPOUND MATRIX - A pellet contains a pharmaceutically active substance embedded in a polymer matrix of one or more water-insoluble polymers; wherein said polymer matrix comprises 10 to 90% by weight of an anionic polymer; with the proviso that the pellet a) releases no more than 10% of said active compound in a release test according to USP in artificial gastric juice at pH 1.2 after 120 min, and b) releases at least 50% of the active compound after altogether a further 300 min at pH 6.8 and/or pH 7.5; wherein said pellet has a particle size in the range from 300 to 1100 μm. | 08-28-2008 |
20080226741 | Cross-linked Polymer Particles - Biodegradable cross-linked particles, as well as related compositions and methods, are disclosed. | 09-18-2008 |
20080226742 | Compositions for Drug Delivery - Substantially non-porous polymeric microparticles comprising a hydrophobic polymer and a plasticizer, and containing therein a bioactive or bioinactive agent. | 09-18-2008 |
20080233201 | Method for Preparing Calibrated Biodegradable Microspheres - The invention relates to a method for preparing monodispersed biodegradable microspheres consisting in a) preparing an emulsion containing at least one polymeric phase and at least one aqueous phase at a viscosity ratio between the dispersed polymeric phase and the aqueous phase ranging from 0.12 to 10, b) exposing the thus obtained emulsion to a controlled laminar shear strength, c) removing a solvent from the polymeric phase and in d) isolating the thus obtained microspheres. The use of the prepared microspheres is also disclosed. | 09-25-2008 |
20080254133 | Microgel Particle - The present invention relates to compositions comprising a pH-responsive microgel particle, wherein the particle is adapted to undergo a conformational change in response to a variation in pH. The compositions may be used as medicaments for treating a disease characterised by damaged or degenerated soft tissues (e.g. intervertebral discs). | 10-16-2008 |
20080254134 | METHOD FOR INDUCING A CELL-MEDIATED IMMUNE RESPONSE AND IMPROVED PARENTERAL VACCINE FORMULATIONS THEREOF - A method of inducing either a T | 10-16-2008 |
20080260850 | Delivery System For Bioactive Agents on the Basis of a Polymeric Drug Carrier Comprising an Amphiphilic Block Polymer and a Polylacticacid Derivative - Delivery system for bioactive agents on the basis of a polymeric drug carrier formed from compositions comprising an amphiphilic block copolymer of a hydrophilic block and a hydrophobic block having a terminal hydroxyl group substituted with a tocopherol or cholesterol group, and a polylactic acide derivative wherein one end of the polylactic acid is covalently bound to at least one carboxyl group. The carboxyl group of the polylactic acid derivative may be fixed with a di- or trivalent metal ion, which is obtained by adding the di- or trivalent metal ion to the polymeric composition. | 10-23-2008 |
20080260851 | Polymeric Nanoparticles and Nanogels for Extraction and Release of Compounds - The invention relates to polymeric nanoparticles and nanogels, which can contain, deliver, and/or release one or more active agents, such as biologically active molecules or fragrance molecules, and methods of preparing the polymeric nanoparticles and nanogels. The nanoparticles are crosslinked utilizing radiation (g-radiation) as the catalyst for free radical polymerization (see FIG. | 10-23-2008 |
20080260852 | SUPERCRITICAL FLUID EXTRACTION PRODUCED BY IN-LINE HOMOGENIZATION - A method for producing micro and/or nanoparticles by contacting an emulsion with a supercritical fluid. The method can be used to produce an aqueous suspension of particles that include a drug encapsulated in a polymer. The drug and polymer are dissolved in an organic solvent to form an organic solution. The organic solution is pumped into contact with an aqueous solution in an in-line homogenization device to form an emulsion. Immediately after the emulsion in the in-line homogenization device, the emulsion contacts the supercritical fluid. The supercritical fluid extracts the organic solvent from the oil droplets of the emulsion, causing the drug and polymer to precipitate into the aqueous phase of the emulsion and thereby form an aqueous suspension of particles that include a drug encapsulated in a polymer. | 10-23-2008 |
20080286377 | ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS - Anti-resorptive bone cements, comprising an anti-resorptive amount of one or more anti-resorptive agents, preferably the anti-resorptive agent is a bisphosphonate. The anti-resorptive bone cements are useful for reducing bone voids and bonding prosthetic devices to bone. The invention also relates to anti-resorptive allogeneic, autografic, and xenografic bone grafts, which bone grafts comprise an anti-resorptive amount of an anti-resorptive agent such as a bisphosphonate. The anti-resorptive bone grafts are useful for reconstructive bone surgery. | 11-20-2008 |
20080292714 | BONE TARGETING OF DEGRADABLE DRUG FILLED NANOPARTICLES - This invention provides a method of modifying a cellular response in a mammal. The method comprises administering to the mammal an effective amount of biodegradable nanoparticles, each of said nanoparticles comprising an active agent, a biodegradable polymer, and a bone targeting agent administering to a mammal an effective amount of a composition comprising a compound absorbed in a biodegradable nanoparticle which is attached to a bone targeting agent. The invention also provides a method for modifying a cellular response in a mammalian cell comprising contacting the mammalian cell with biodegradable nanoparticles. The invention further provides a method of delivering an exogenous substance to a mammal. The method comprises administering to the mammal a composition comprising the exogenous substance absorbed into a biodegradable nanoparticle, wherein the biodegradable nanoparticle is covalently attached to a bone targeting agent. The invention also provides a composition and a process for preparing the composition comprising a biologically active or therapeutic agent of compound, a biodegradable nanoparticle, and a bone targeting agent. | 11-27-2008 |
20080305175 | Micro-Container - There is disclosed a method of making a micro-container. The method comprises the step of evaporating a swelling agent solution absorbed in a polymer micro-particle to form an inner void therein. The evaporating step is undertaken under conditions to form a conduit extending through the shell wall of said micro-particle and into the inner void. | 12-11-2008 |
20080305176 | Process For Loading Polymer Particles With Drug - The present invention relates to processes for loading microsphere polymer particles with crystallisable drug, in the presence of a crystallisation inhibitor whereby crystallisation of the drug is inhibited. The invention is of particular value for loading polymer beads with paclitaxel, ibuprofen and/or dexamethasone. The polymer is suitably an anionic polyvinyl alcohol polymer. | 12-11-2008 |
20090004286 | COMPOSITIONS FOR ACHIEVING A THERAPEUTIC EFFECT IN AN ANATOMICAL STRUCTURE AND METHODS OF USING THE SAME - Compositions and methods of using the compositions to achieve a therapeutic effect are provided. | 01-01-2009 |
20090011038 | Drug-Delivery Systems - The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterised in that at least one signal substance for transport through a biological barrier and at least one active ingredient are stored, the support, signal substance and active ingredient having no covalent links and no active-ingredient specific and signal substance specific coordinative links between one another. | 01-08-2009 |
20090011039 | Modified-release particles of polyelectrolytes and pharmaceutical formulations thereof - The present invention relates to novel particles comprising polyelectrolyte polymers which are transporters of active principle (AP), in particular protein and peptide active principle, and to novel modified-release pharmaceutical formulations comprising said AP microparticles. | 01-08-2009 |
20090011040 | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases - The present invention is a method of using compacted nucleic acid (such as DNA) nanoparticles for non-viral gene transfer to various tissues of the human eye or eyes of other mammals. These nanoparticles comprise, in one embodiment, a neutrally-charged complex containing a single molecule of plasmid DNA compacted with polyethylene glycol (PEG)-substituted poly lysine peptides. | 01-08-2009 |
20090028957 | Implantable Tissue-Reactive Biomaterial Compositions and Systems, and Methods of Us Thereof - The invention pertains to biomaterial compositions and implantable systems for application to a tissue site in a living mammalian body. The compositions and systems react with tissue surfaces and components present in physiological fluids at the region of implantation, obviating the need to remove such fluids and improving the adhesion and resorption rate of the resulting bioimplant. Delivery devices and methods of use are also provided. | 01-29-2009 |
20090035381 | ELECTROSPRAYING METHOD FOR FABRICATION OF PARTICLES AND COATINGS AND TREATMENT METHODS THEREOF - Electrospray systems and modified electrospray systems for the fabrication of core-shell particles for controlled-release and/or sustained-release treatment and delivery are herein disclosed. The electrospray system may include between one and a plurality of co-axially situated tubes. Each tube may be electrically connected to a power supply wherein a voltage may be applied thereto. Core-shell particles may be collected on a collection target, which may be a wet or dry collector, and electrically connected to the power supply. Core-shell particles and methods of manufacture are also disclosed. The precursors of the core-shell particles may be polymer- or biomacromolecule-based solutions and may include at least one treatment agent incorporated therein. The number of “core” particle(s) within the “shell” may vary and may provide different treatment agent release profiles depending on the material and/or chemical characteristics of the polymer and/or biomacromolecule used. Methods of treating a condition are also disclosed. A treatment may include delivery of a plurality of core-shell particles which include a treatment agent to a treatment site. Delivery may be performed by a surgical procedure or by a non-invasive procedure such as catheter delivery. | 02-05-2009 |
20090041851 | Composition for the delivery of live cells and methods of use thereof - The invention relates to an improved method for administering live cells to a patient and compositions useful in the method. The composition comprises live cells and biocompatible, biodegradable polymer microparticles. The cells and microparticles of the cell/microparticle composition can be contacted immediately prior to administration, or can be contacted in culture for a specified period of time prior to administration. In the method of the invention, an effective amount of the cell/microparticle composition is administered to a patient in need thereof by injection to a treatment site of the patient to provide a therapeutic effect in the patient. The therapeutic effect can be, for example, the formation of new tissue at the treatment site, or the production and secretion of a biologically active secretory molecule at the treatment site. The therapeutic effect resulting from injection of the cell/microparticle composition into a treatment site, is determined by the type of cell present in the composition. The composition comprising lives cells and biocompatible, biodegradable polymer microparticles can further comprise a biologically active agent. In a preferred embodiment, the biologically active agent is incorporated into the microparticle. The biologically active agent can be, for example, factors which modulate cell growth. | 02-12-2009 |
20090041852 | DRY POWDER COMPOSITIONS AND SYSTEMS FOR POULTRY VACCINATION - This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or non-reducing sugar and a biocompatible polymer, said dry powder composition being in the form of particles having an average particle size from 2 to 30 μm and a particle size polydispersity from 1.1 to 4.0. This invention also relates to a method for producing said dry powder compositions and a system for vaccination of poultry by inhalation. | 02-12-2009 |
20090053318 | Forming Embolic Particles - Methods of making polymer particles, as well as related particles, compositions, and methods are disclosed. | 02-26-2009 |
20090061009 | Composition and Method of Treatment of Bacterial Infections - The invention is intended for a treatment of severe infections using an injectable drug-delivery system comprising nanoparticles of a biodegradable polymer with incorporated antibacterial drug. | 03-05-2009 |
20090061010 | CANCER CELL TARGETING USING NANOPARTICLES - The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries. | 03-05-2009 |
20090061011 | COMPOSITIONS AND METHODS FOR DELIVERY OF POORLY SOLUBLE DRUGS - Described herein are compositions comprising particles of poorly soluble drugs encapsulated by stabilizers. Further described are pharmaceutical compositions comprising such encapsulated compositions. Also described are methods of making such encapsulated particle compositions, and methods of making the corresponding pharmaceutical compositions. The encapsulated particle compositions described herein allow poorly soluble drugs to be administered with good bioavailability by routes that are non-invasive to patients, such as by oral administration. | 03-05-2009 |
20090068280 | Controlled Release Interferon Drug Products and Treatment of HCV Infections Using Same - The invention relates to controlled release formulations comprising a microparticle comprising a biodegradable polymer and one or more interferon compounds and methods of using the formulations. | 03-12-2009 |
20090081309 | Stabilized Oral Suspension Formulation - Orally deliverable pharmaceutical compositions are provided comprising a drug of tow water solubility suspended in an aqueous liquid vehicle comprising a wetting agent, a thixotropic thickening agent, and an inorganic suspending agent. The compositions are thixotropic, substantially deflocculated, and substantially physically stable. | 03-26-2009 |
20090092675 | COMPOSITIONS CONTAINING MULTIPLE POLYMERS AND PARTICLES MADE USING THE COMPOSITIONS - The compositions described herein include a first polymer that is either a polyvinyl alcohol or a polyvinyl formal, and a second polymer that is one of a polyvinyl alcohol, a polyvinyl formal, polyvinylpyrrolidone, a polysaccharide, or a polymethacrylate. The first polymer and the second polymer in the composition are different. These compositions are useful in the formation of particles, such as embolic particles, or other medical devices. The compositions are also useful in the delivery of therapeutic agents. Different ratios of the first polymer to the second polymer can provide different rates of release of the therapeutic agent from the composition. | 04-09-2009 |
20090092676 | CROSS-LINKED POLYMER PARTICLES - Cross-linked polymer particles, as well as related compositions and methods, are disclosed. | 04-09-2009 |
20090092677 | MULTI-COMPONENT PARTICLES FOR INJECTION AND PROCESSES FOR FORMING THE SAME - In accordance with one aspect of the invention, novel compositions containing injectable particles are provided in which the injectable particles contain at least two polymeric components that differ in composition from one another (e.g., because at least one polymeric component contains a polymer that is not present in another polymeric component). | 04-09-2009 |
20090104277 | Preparation of Molecular Imprinted Polymers - One aspect is a method for improved preparation of molecular imprinted polymer (MIP) particles, where initial compositions comprising insoluble MIP particles are enriched for those MIP particles that bind a particular target molecule, thus excluding non-binding and weakly binding particles from the final composition. Enrichment is typically accomplished via use of chromatographic methods capable of separating particulate material or by means of agglutination. Another aspect is preparation of improved insoluble MIPs by use of extended micronization of raw MIP particles with a view to expose a large number of binding sites per mass unit of MIP particles. In preferred embodiments the two aspects are combined. The resulting improved MIPs may be used for diagnostic, analytical and therapeutic purposes, notably as orally administered drugs which can bind substances such as cholesterol and bile acids and bile acid salts in the gastrointestinal tract. | 04-23-2009 |
20090110744 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS - A sustained release microsphere composition comprising—
| 04-30-2009 |
20090117196 | Polyvinyl Alcohol Microspheres, Injectable Solutions and Therapeutic Uses of the Same - The present invention relates to microspheres useful for embolization which comprises polyvinylalcohol. The present invention also relates to an injectable suspension suitable for embolization which comprises the polyvinylalcohol microspheres and a suitable liquid carrier. The present invention further relates to a method for prophylactic or therapeutic embolization which comprises administering to a mammal an injectable suspension containing the polyvinylalcohol microspheres and a suitable liquid carrier. Finally, the present invention relates to a process for producing the polyvinylalcohol microspheres. | 05-07-2009 |
20090123555 | Stimulateable Polymer Particles Exhibiting Reactive Functions, Method for the Production and the Use Thereof - The invention relates to spherical particles formed by polymer chains containing approximately from 30 to 10000 monomer units derived from monocyclic polycyclic alkene polymerization, wherein at least one monomer unit is substituted by an R chain including ethylene polyoxide which is optionally covalently linked to the polymer units through a hydrolyzable bridge and substituted by a reactive function, optionally engaged in a link with an active principle or a biological molecule such as protein, wherein the chain R is covalently linked to the monomer units. The use of the inventive spherical particles for preparing pharmaceutical and cosmetic compositions or surface coatings is also disclosed. | 05-14-2009 |
20090123556 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS - The present invention provides a sustained release microsphere composition comprising | 05-14-2009 |
20090136585 | SURFACE-MODIFIED NANOPARTICLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS AND COMPOSITION FOR MAKING SAME - Surface-modified polymeric nanoparticles (NPs), compositions for making them, and their use in drug delivery are disclosed. | 05-28-2009 |
20090142408 | Telomerase delivery by biodegradable Nanoparticle - A therapeutic compound consisting of human telomerase, its catalytic subunit hTert, or a known variant of either, and a biodegradable nanoparticle carrier, which can be administered to cells in a cell culture or in a living animal, is provided herein. The therapeutic compound is envisioned as a method for treating a wide variety of age-related diseases such as idiopathic pulmonary fibrosis, aplastic anemia, dyskeratosis congenita, arteriosclerosis, macular degeneration, osteoporosis, Alzheimer's, diabetes type 2, and any disease that correlates with telomere shortening and may be corrected or ameliorated by lengthening telomeres. The therapeutic compound is also envisioned as method for potentially treating more generic problems of human aging. The nanoparticle carrier is comprised of certain biodegradable biocompatible polymers such as poly(lactide-co-glycolide), poly(lactic acid), poly(alkylene glycol), polybutylcyanoacrylate, poly(methylmethacrylate-co-methacrylic acid), poly-allylamine, polyanhydride, polyhydroxybutyric acid, polycaprolactone, lactide-caprolactone copolymers, polyhydroxybutyrate, polyalkylcyanoacrylates, polyanhydrides, polyorthoester or a combination thereof. The nanoparticle may incorporate a targeting moiety to direct the nanoparticle to a particular tissue type or a location within a cell. The nanoparticle may incorporate a plasticizer to facilitate sustained release of telomerase such as L-tartaric acid dimethyl ester, triethyl citrate, or glyceryl triacetate. A nanoparticle of the present invention can further contain a polymer that affects the charge or lipophilicity or hydrophilicity of the particle. Any biocompatible hydrophilic polymer can be used for this purpose, including but not limited to, poly(vinyl alcohol). | 06-04-2009 |
20090155375 | Compositions comprising a lipid and copolymer of styrene and maleic acid - A composition comprising a lipid and copolymer of styrene and maleic acid, wherein the copolymer of styrene and maleic acid is non-alternating, and wherein the polymer and lipid are in the form of macromolecular assemblies. | 06-18-2009 |
20090169641 | COMPRESSIBLE PARTICLES - Disclosed herein are methods that include providing a first particle having pores, the first particle having a first compression test value, and partially cross-linking the first particle to form a second particle having pores, the second particle having a second compression test value that is larger than the first compression test value by 25% or more, where a maximum dimension of the first particle is 5,000 microns or less, and a maximum dimension of the second particle is 5,000 microns or less. | 07-02-2009 |
20090186094 | Injectable and Swellable Microspheres for Tissue Bulking - The present invention relates to injectable compositions comprising biocompatible, swellable, hydrophilic, non-toxic and substantially spherical microspheres useful for tissue bulking. The invention also relates to methods of tissue bulking, particularly for the treatment of Gastro-esophageal reflux disease, urinary incontinence, or urinary reflux disease, using the injectable compositions. | 07-23-2009 |
20090196936 | Hydrogel wound dressing and biomaterials formed in situ and their uses - The present invention relates to a method of forming shape-retentive and shape-conforming aggregate wound dressings and biomaterials composed of gel nanoparticles and wound or bodily fluid in which the aggregates are held together by non-covalent bond physical forces such as, without limitation, hydrophobic-hydrophilic interactions and hydrogen bonds. The method comprises introducing a dry powder of gel nanoparticles to a wound site in which the nanoparticles absorb some of the blood or wound exudate and coalesce in situ into the claimed shape-retentive aggregate dressing. The method also comprises introducing the dry nanoparticle powder in or on a wet bodily tissue in vivo to form the claimed shape-retentive biomaterial. In addition, the method also comprises incorporating biomedical agents to produce medicated aggregate dressings or biomaterials for a variety of medical applications. This invention also relates to uses of the method of formation of the shape-retentive aggregates of gel nanoparticles. | 08-06-2009 |
20090196937 | TEMPERATURE-SENSITIVE NANO-CARRIERS - The present invention relates to a process of preparing a biocompatible temperature-sensitive nano-carrier, which comprises the steps of (a) preparing a polymer dispersion comprising a water-soluble biocompatible polymer with photo-crosslinkable functional group(s), (b) preparing a polymer-initiator solution by adding an initiator to the polymer dispersion, and (c) preparing the nano-carrier by irradiating light onto the polymer-initiator solution, wherein the average diameter of the nano-carrier changes depending on temperature, and also relates to a temperature-sensitive nano-carrier. Nano-carriers of the present invention are temperature-sensitive, and their average diameter and pore size reversibly change in response to temperature change. In an embodiment of the present invention, nano-carriers can be prepared via a one-pot single-phase synthesis. A process of the present invention overcomes the conventional problems such as the use of organic solvent, complicated preparation steps, a relatively high manufacture cost and a low loading efficiency. Moreover, a process of the present invention can ensure the stability of drugs without necessitating high-speed homogenization or ultrasonification generally carried out in the conventional process. | 08-06-2009 |
20090208586 | porous bioabsorbable material and method of producing the same - [Problems] To provide a thin film-shaped porous bioabsorbable material that is a dense structure in which the pore size average is small and the pore size is uniform and which further has a large maximum stress, in particular, a porous bioabsorbable material extremely useful as an adhesion preventing material. | 08-20-2009 |
20090214667 | Medical technical product, method for producing the same and providing the same for surgery - A medicotechnical product for adhesion prophylaxis for the post-operative prevention of accretions in the body comprises at least one PVA (polyvinyl alcohol) selected from the group comprising uncrosslinked PVA with a molecular weight of 15,000 to 400,000, crosslinked PVA and mixtures thereof. The molecular weight of the PVA or the mixture is selected in such a way that it can be excreted via the kidneys substantially with no degradation of the PVA molecules. | 08-27-2009 |
20090220614 | Thermo-Responsive Block Co-Polymers, and Use Thereof - Provided are thermo-responsive polymersomes, which display cold-controlled encapsulation near the physiological temperatures, and have a PDI less than 1.2. Morphology of the thermo-responsive polymersomes is a function of the weight fraction of the hydrophilic block in the block copolymer and the number average molecular weight (M | 09-03-2009 |
20090220615 | Main Chain Acid-Degradable Polymers for the Delivery of Bioactive Materials - Novel main chain acid degradable polymer backbones and drug delivery systems comprised of materials capable of delivering bioactive materials to cells for use as vaccines or other therapeutic agents are described. The polymers are synthesized using monomers that contain acid-degradable linkages cleavable under mild acidic conditions. The main chain of the resulting polymers readily degrade into many small molecules at low pH, but remain relatively stable and intact at physiological pH. The new materials have the common characteristic of being able to degrade by acid hydrolysis under conditions commonly found within the endosomal or lysosomal compartments of cells thereby releasing their payload within the cell. The materials can also be used for the delivery of therapeutics to the acidic regions of tumors and other sites of inflammation. | 09-03-2009 |
20090232899 | Mucoadhesive nanocomposite delivery system - A nanocomposite delivery system uses chitosan as a mucoadhesive material encapsulated in a surface modified network of colloidal nanoporous nanoparticles, such as silica, or other colloid-forming materials, especially metal oxides. Drug delivery systems may be provided by binding a drug to the chitosan/silica nanocomposite, typically by adding a drug or other active agent during in-situ gellation of colloidal silica. When the active agent is, for example, amoxicillin or other antibiotic agent, the drug delivery system may be used in the treatment of stomach ulcers, for example. | 09-17-2009 |
20090232900 | NANO-MICELLAR PREPARATION OF ANTHRACYLCLINE ANTITUMOR ANTIBIOTICS ENCAPSULATED BY THE PHOSPHATIDE DERIVATIZED WITH POLYETHYLENE GLYCOL - The present invention provides a nano-micellar preparation of anthracycline antitumor antibiotics for intravenous injection, which comprises a therapeutically effective amount of anthracycline antitumor antibiotics, a phosphatide derivatized with polyethylene glycol, together with pharmaceutically acceptable adjuvants. The preparation is prepared by encapsulating the medicament with a nano-micelle to obtain the nano-micellar preparation of anthracycline antitumor antibiotics for injection. The anthracycline antitumor antibiotics and the phosphatide derivatized with polyethylene glycol form a nano-micelle with a highly homogeneous particle size. In the micelle, the hydrophobic core of encapsulated medicament is surrounded by polyethylene glycol molecules to form a hydrophilic protective layer, so that the medicament is prevented from contacting with the enzymes and other protein molecules in blood and being recognized and phagocytozed by reticuloendothelial system in the body, and the circulation time in vivo of the micelle is prolonged. | 09-17-2009 |
20090232901 | POLYMERIC MICROSPHERES - The invention features core-shell microsphere compositions, hollow polymeric microspheres, and methods for making the microspheres. The microspheres are characterized as having a polymeric shell with consistent shell thickness. | 09-17-2009 |
20090238890 | CONTINUOUS SPRAY-CAPTURE PRODUCTION SYSTEM - The disclosure relates to novel microencapsulation processes based on the use of high viscosity fluids (e.g., gelatinized starch and alginate), which are mixed and then sprayed using a much gentler hydraulic pressure and, preferably gas-based atomization into a crosslinking solution (e.g. of calcium chloride). To improve the efficiency of the system, the process can be performed in a continuous mode rather than by a conventional batch process. This involves continuous or intermittent harvest of the microparticles collected in the capture vessel followed by amendment and recycling of the CaCl | 09-24-2009 |
20090252811 | CAPPED MESOPOROUS SILICATES - The invention provides an article comprising, a mesoporous silicate matrix, such as a particle, having one or more pores; and one or more releasable caps obstructing one or more of the pores. The articles are useful as delivery vehicles for encapsulated agents such as therapeutic agents, polynucleotides, polypeptides and the like. | 10-08-2009 |
20090269414 | PROCESS OF PREPARING MICROSPHERES FOR SUSTAINED RELEASE HAVING IMPROVED DISPERSIBILITY AND SYRINGEABILITY - Disclosed is a process of preparing sustained release microspheres, containing a biodegradable polymer as a carrier and a drug, using spray drying. The process comprises preparing a solution, suspension or emulsion containing a biodegradable polymer, a drug and a solvent; spray drying the solution, suspension or emulsion; and suspending spray-dried microspheres in an aqueous solution containing polyvinyl alcohol to remove the residual solvent and increase the hydrophilicity of the microsphere surface. The process enables the preparation of microspheres having high drug encapsulation efficiency, almost not having a toxicity problem due to the residual solvent, and having good syringeability. The microspheres prepared according to the present invention release an effective concentration of a drug in a sustained manner for a predetermined period when administered to the body, and are thus useful in the treatment of diseases. | 10-29-2009 |
20090297621 | Microparticles For The Treatment Of Disease - Microparticle-bioactive agent based treatments for local treatment of diseased tissues/organs are disclosed. | 12-03-2009 |
20090304806 | Pharmaceutical Compositions - A process for the production of a composition comprising a water-insoluble sartan which comprises the steps of: a) providing a mixture comprising: i) a water-insoluble sartan, ii) a water soluble carrier, iii) a solvent for each of the sartan and the carrier, and b) spray-drying the mixture to remove the or each solvent and obtain a substantially solvent-free nano-dispersion of the sartan in the carrier. | 12-10-2009 |
20090317479 | NANOPARTICLES CONTAINING WATER-SOLUBLE NON-PEPTIDE LOW-MOLECULAR WEIGHT DRUG - Drug-containing nanoparticles are provided that enable effective targeting and sustained-release of a water-soluble, non-peptide, low-molecular weight drug and cause reduced accumulation of the drug in the liver. The nanoparticles containing a water-soluble, non-peptide, low-molecular weight drug are obtained by hydrophobicizing the water-soluble, non-peptide, low-molecular weight drug by a metal ion, and reacting the hydrophobicized drug with a poly(lactic acid)-polyethylene glycol block copolymer or a poly(lactic-co-glycolic acid)-polyethylene glycol block copolymer. The nanoparticles have favorable targeting and sustained-release properties and cause reduced accumulation of the drug in the liver. | 12-24-2009 |
20090317480 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-II - The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds. | 12-24-2009 |
20090317481 | MODAFINIL FORMULATIONS - The invention provides an oral pharmaceutical composition comprising modafinil particles, wherein at least about 5% of said modafinil particles have a diameter greater than 200 microns. | 12-24-2009 |
20100003337 | FUNCTIONALIZED POLY(ETHER-ANHYDRIDE) BLOCK COPOLYMERS - The present application is directed to biodegradable polymers, compositions, including microspheres and nanospheres, formed of such polymers, and methods of using such polymers and compositions. In certain embodiments, the subject polymer compositions include therapeutic agents, optionally providing sustained release of the encapsulated agent after administration to a patient. | 01-07-2010 |
20100003338 | Micelles for delivery of nitric oxide - Embodiments include a vehicle for delivery of nitric oxide comprising: a collection of micelles having an internal micelle core that comprises a polymer with N-diazeniumdiolate comprising NO complexed with secondary amines of the polymer. Embodiments include a method of making a nitric oxide vehicle comprising dissolving a polymer that comprises secondary amines in an aqueous solution and combining the polymer with nitric oxide in the solution to form a N-diazeniumdiolate comprising the nitric oxide complexed with the secondary amines, with the formation of the N-diazeniumdiolate causing the polymer to be at least partially insoluble in the solution and to form a collection of micelles that have an internal core that comprises N-diazeniumdiolate. | 01-07-2010 |
20100028454 | Preparation method for biodegradable micro-particles containing drugs - The disclosure provides a method to form sustained release drug-containing microparticles with a biodegradable polymer. The method involves forming a polymer-drug-organic solvent phase, and dispersing the polymer-drug-organic solvent phase in an aqueous suspension of an inorganic gel, which may be hydroxyapatite. The hydroxyapatite appears to coat the polymer-drug-solvent droplets to prevent them coalescing. The solvent then evaporates with stirring of the dispersion, at which time the droplets solidify to drug-containing microparticles. The inorganic gel allows suitably small microparticles to form without use of an organic emulsifier. | 02-04-2010 |
20100040697 | COSMETIC PRODUCT, NANOPARTICLES FOR COSMETICS, AND POWDER FOR COSMETICS - The invention provides a cosmetic product which has a good texture and allows full expression of the inherent functions of ceramide as an intercellular lipid, such as skin barrier function and hair protection effect, as well as nanoparticles for cosmetics and powder for cosmetics which may be used in the above cosmetic product, exhibit good skin barrier function and hair protection effect, and are easy to incorporate into the above cosmetic product. The cosmetic product, the nanoparticles, and the powder for cosmetics according to the present invention contain a polymer obtained by polymerization of a monomer material containing a glycerol (meth)acrylate monomer represented by the formula (1): | 02-18-2010 |
20100080852 | PHAMACEUTICAL COMPOSITION COMPRISING NANOPARTICLES AND CASEIN - A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and a poorly aqueous soluble non-ionizable polymer, and casein. | 04-01-2010 |
20100086614 | NANOPARTICULATED ANESTHETIC COMPOSITION FOR TOPIC USE - The present invention relates to a nanoparticulated anaesthetic composition for topical use in which at least one local anaesthetic agent is encapsulated in polymeric nanoparticles. The present invention also relates to the use of such polymeric nanoparticles comprising at least one local anaesthetic agent in the preparation of an anaesthetic composition for topical application to the skin or mucosa. | 04-08-2010 |
20100086615 | AGENT FOR TREATMENT OF PULMONARY DISEASE - To provide a pulmonary disease therapeutic drug exhibiting high efficacy and reduced side effects. | 04-08-2010 |
20100098772 | DRUG DELIVERY SYSTEMS AND METHODS FOR TREATING NEOVASCULARIZATION - Anti-angiogenesis compositions, and methods of using such compositions, useful for intraocular to treat neovascularization. The compositions can have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps. | 04-22-2010 |
20100098773 | POLYMER VESICLES FOR SELECTIVE ELECTROMAGNETIC ENERGY-INDUCED DELIVERY - Provided are polymer vesicles comprising polymersomes, a radiofrequency absorbing moiety, a protein or a polysaccharide associated with the inner leaflet of the membrane and a therapeutic or diagnostic cargo. The invention also concerns the use of these polymer vesicles for selective electromagnetic energy-induced delivery of therapeutic or diagnostic agents. | 04-22-2010 |
20100104654 | PROSTAGLANDIN AND PROSTAMIDE DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF - Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma. | 04-29-2010 |
20100104655 | Therapeutic Polymeric Nanoparticles Comprising Vinca Alkaloids and Methods of Making and Using Same - The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a vinca alkaloid; and about 50 to about 99 weight percent biocompatible polymer. | 04-29-2010 |
20100104656 | Meltable Binder for Melt Granulation and/or Pelletization - A low melting binder composition for preparation of pharmaceutical tablets and/or granules which comprises a polymer and a hydrophobic meltable binder. | 04-29-2010 |
20100112078 | POLYMER PARTICLES BASED VACCINE - The present invention provides a vaccine composition comprising an effective amount of antigen or a nucleic acid encoding antigen, encapsulated in polymeric particles, wherein said polymeric particles comprises nanoparticles, microparticles or combinations thereof, wherein surprisingly the nanoparticle induces cellular response and the microparticle induces humoral response. The invention further provides a method of inducing cellular and/or humoral immune response. | 05-06-2010 |
20100112079 | Thyroid Hormone Analogs and Methods of Use - Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed. | 05-06-2010 |
20100136130 | Preparation for the Controlled Release of Bioactive Natural Substances - The present invention relates to a preparation comprising at least one encapsulation material and at least one bioactive natural substance, which bioactive natural substance can be released from the preparation in a controlled manner, wherein the encapsulation material comprises at least one glyceride with a melting point of at least 35° C. and additionally at least one polymer with polyester units, which has a melting temperature of at least 30° C. and a viscosity in the range from 50 mPa*s to 250 Pa*s, measured by means of rotational viscometry at 110° C. The present invention further describes processes for producing the preparation of the invention, as well as preferred uses. | 06-03-2010 |
20100166876 | LOADING OF HYDROPHOBIC DRUGS INTO HYDROPHILIC POLYMER DELIVERY SYSTEMS - A process is described for loading hydrophilic polymer particles with a water-insoluble solvent-soluble drug. The particles are preferably embolic agents. The method provides particles having little or no drug at the surface and in a surface layer, whereby the burst effect is minimised. The drug is precipitated in the core of the particle, leading to extended release. The drug is, for instance, paclitaxel, rapamycin, dexamethasone or ibuprofen. | 07-01-2010 |
20100183732 | Novel one step process for preparing cross-linked poly(allylamine) polymers - The present invention relates to a novel one step process for preparing cross-linked poly(allylamine) polymers or salts thereof using the novel cross-linking agent of Formula (IV). This invention also relates to the compound of Formula (IV) as well as to a process to obtain it. The cross-linked poly(allylamine) polymers of the invention are useful in medicine as substrate-binding polymers. | 07-22-2010 |
20100203153 | SUSTAINED-RELEASE NANOPARTICLE COMPOSITIONS AND METHODS USING THE SAME - The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition. | 08-12-2010 |
20100209525 | METHODS FOR PREPARING POLYMER MICROPARTICLES - The present invention describes methods and tools for preparing a population of monodisperse polymer microparticles, which are of particular interest in the field of drug delivery. | 08-19-2010 |
20100226997 | CONTROLLED-RELEASE OPHTHALMIC VEHICLES - An ophthalmically acceptable vehicle includes an aqueous suspension having a first viscosity. The suspension includes about 0.1% to about 6.5% by weight of a carboxyl-containing polymer prepared by polymerizing one or more carboxyl-containing monoethylenically unsaturated monomers and less than about 5% by weight of a cross-linking agent. The polymer has average particle size of not more than about 50 μm in equivalent spherical diameter. The vehicle includes a second polymer that allows the carboxyl-containing polymer to remain suspended. Upon contact with tear fluid, the vehicle gels to a second viscosity which is greater than the first viscosity. A method of administering a medicament to the eye of a subject includes applying a composition that includes this ophthalmically acceptable vehicle and a medicament contained for treatment of a disease or disorder for which ophthalmic delivery is indicated. The medicament is released from the vehicle in a sustained release manner. | 09-09-2010 |
20100239685 | COMPOUND FOR TREATMENT OR PREVENTION OF PROSTATE-RELATED DISEASES AND PHARMACEUTICAL COMPOSITION OF COLON DELIVERY SYSTEM CONTAINING THE SAME - Provided is a naphthoquinone-based compound represented by Formula 1 or 2 having therapeutic effect on the treatment and/or prevention of prostate and/or testicle (seminal glands)-related diseases, and to a pharmaceutical composition of intestinal delivery system containing the same. | 09-23-2010 |
20100247666 | Method for Preparing Suspensions of Low-Solubility Materials - A process for producing a pharmaceutical suspension that comprises an active pharmaceutical ingredient (“API”) having low solubility, the process comprises: (a) preparing a first solution comprising a carboxy-containing vinyl polymer and a solvent; and (b) adding a compound of the API to said first solution under conditions of high-shear mixing for a time from about 5 minutes to about 5 hours, said compound being soluble in said solvent, thereby producing a suspension of particles of said API in a composition comprising said carboxy-containing vinyl polymer; wherein a concentration of said API in said suspension is higher than a solubility of said API in said solvent. The present invention also provides a suspension produced by such process. | 09-30-2010 |
20100247667 | MATERIAL FOR SOFT TISSUE ENLARGEMENT - A soft tissue enlarging material including fine particles of a pH-response water-absorbing swelling polymer having an average particle size of from 15 μm to 40 μm wherein swelling of said particles is completed within 10 minutes after immersion in a 10 mM phosphate buffer physiological saline solution (pH: 7) at 37° C. | 09-30-2010 |
20100247668 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE - Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles. | 09-30-2010 |
20100247669 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE - Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles. | 09-30-2010 |
20100255112 | Efficient Nuclear Delivery of Antisense Oligonucleotides or siRNA In Vitro and In Vivo by Nano-Transforming Polymersomes - Provided is a biocompatible polyethylene oxide (PEO)-based polymersome system for the delivery of oligonucleotides, including antisense RNA, siRNA and RNAi, to a cell or tissue target, and method of use therefore, wherein the method comprises encapsulating the oligonucleotide in a biodegradable neutral, nano-transforming polymersome delivery vehicle and delivering the encapsulated oligonucleotide to the cell or tissue target in vitro or in vivo, particularly for treating a disease, such cancer or cellular hyperproliferation. The degradable polymersome, and the oligonucleotides stably encapsulated therein are taken up passively by cells and delivered into endolysosomes, wherein the polymersomes decompose at a known rate at a known pH, thereby releasing encapsulated oligonucleotides in a controlled manner within the cell and facilitating delivery of antisense oligonucleotide or siRNA or RNAi into the nucleus of the cell target. | 10-07-2010 |
20100272821 | Cosmetic Composition for External Administration in Spray Form - Cosmetic composition for external administration in spray form. The present invention refers to a cosmetic composition for external administration in spray form and to a production process of this cosmetic composition containing at least an active compound, a continuous external dispersing phase (natural mineral spring water and/or wine), sodium polyphosphate, sodium polyacrylate and citric acid. The present invention also refers to a dosing and application device for this composition and to the use thereof for the production of a cosmetic composition of external use in spray form. | 10-28-2010 |
20100272822 | NANOCELL DRUG DELIVERY SYSTEM - Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antiangiogenic agent. | 10-28-2010 |
20100278931 | POROUS SILICON DRUG-ELUTING PARTICLES - The invention provides a biodegradable drug-eluting particle useful for the delivery of diagnostic or therapeutic agents. In certain embodiments, the drug-eluting particle of the invention comprises a biodegradable porous silicon body, a reservoir formed within the porous silicon body having at least one opening to an exterior of the body, wherein the reservoir contains a therapeutic or diagnostic agent, and an agent-permeable seal disposed over the at least one opening. The invention further provides a method for treating a patient to obtain a desired local or systemic physiological or pharmacological effect comprising administering a sustained release drug delivery particle of the invention. The invention also provides methods of fabricating a drug-eluting particle for releasing therapeutic agents | 11-04-2010 |
20100278932 | POLYMER MICELLES CONTAINING SN-38 FOR THE TREATMENT OF CANCER - The present invention provides micelles having SN-38 encapsulated therein. | 11-04-2010 |
20100285144 | POLYMER-EPOTHILONE CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE - Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer or neurological deficits. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles. | 11-11-2010 |
20100297250 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS - 1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate. | 11-25-2010 |
20100297251 | ENCAPSULATED PARTICLES FOR ENTERIC RELEASE - The present invention provides a system for delivery of an enteric coated active agent generally resistant to disintegration in an neutral environment having one or more active agents encapsulated by a polymer coating formed by chemical vapor deposition of one or more monomers on the one or more active agents to form a chemical vapor deposition polymer coating that controls the release of the one or more active agents in the gastrointestinal tract. | 11-25-2010 |
20100297252 | NANOPARTICULATE MELOXICAM FORMULATIONS - The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm. | 11-25-2010 |
20100303922 | METHOD FOR THE PREPARATION OF BIOCOMPATIBLE POLYMERIC NANOPARTICLES FOR DRUG DELIVERY AND NANOPARTICLES PREPARED THEREBY - Disclosed are biocompatible polymeric nanoparticles for drug delivery and a method for preparing the same. They can be prepared by mixing a tri-block copolymer, PEG, and a drug at a predetermined temperature to give a homogeneous polymeric mixture; solidifying the homogeneous polymeric mixture at room temperature; and dissolving the solidified polymeric mixture in an aqueous solution. Based on a polymer melting process, the method makes it easy to produce poloxamer nanoparticles at low cost. The nanoparticles show desired particle sizes suitable for use in drug delivery and a uniform particle size distribution. Consisting of a bilayer structure, the nanoparticles can contain sparingly soluble drugs. Also, the nanoparticles contain no organic solvents and are thus safe to the body because they are free of organic solvent residuals. Further, after being administered into the body, the nanoparticles with a high content of sparingly soluble drug entrapped therein can safely deliver the drug to target sites and stably release the drug at a controlled rate. | 12-02-2010 |
20100303923 | Endotoxin adsorbent for the prevention and treatment of autoimmune diseases - It is believed that the abnormal absorption of endotoxin present in the gastrointestinal tract relates to the pathogenesis of autoimmune diseases such as rheumatoid arthritis. In an animal model for rheumatoid arthritis, it is observed that arthritis is improved by removing endotoxin. The present invention provides an endotoxin-adsorbent, which is capable of removing endotoxin in the gastrointestinal tract and can be administered to humans safely. By using a non-digestible and non-absorbable, and therefore, safe endotoxin-adsorbent, which has a high endotoxin-binding capacity for removing large amounts of endotoxin present in the gastrointestinal tract, it is possible to prevent and treat autoimmune diseases such as rheumatoid arthritis. | 12-02-2010 |
20100310670 | SUSTAINED-RELEASE MICROSPHERE CONTAINING SHORT CHAIN DEOXYRIBONUCLEIC ACID OR SHORT CHAIN RIBONUCLEIC ACID AND METHOD OF PRODUCING THE SAME - A sustained-release microsphere formulation containing a short chain deoxyribonucleic acid or a short chain ribonucleic acid as an active ingredient, which has improved sustained-release properties and long-lasting efficacy, is provided. A fine particle formulation, encapsulating stably a short chain deoxyribonucleic acid or a short chain ribonucleic acid, being capable of inhibiting, for a long period, expression of a specific protein related to a disease, and which can be administered by injection or transmucosally, and a production method of the same are provided. A sustained-release microsphere formulation containing a short chain deoxyribonucleic acid or a short chain ribonucleic acid, particularly siRNA, as an active ingredient, especially a sustained-release microsphere prepared through a w | 12-09-2010 |
20100310671 | ENCAPSULATED LOW VISCOSITY HYDROPHOBIC LIQUID ACTIVES - The present invention provides personal care compositions, as well as methods for protecting low viscosity hydrophobic liquid actives. | 12-09-2010 |
20100323026 | SUSTAINED RELEASE PREPARATION FOR TISSUE REGENERATION THERAPY - The object of the present invention is to provide a microsphere which has a slow-release period of from about two weeks to about four weeks following administration, enables a higher content of a drug to be included, suppresses an initial burst of the drug, and enables the drug to be maintained at an optimal, effective blood concentration during the slow-release period. | 12-23-2010 |
20110008456 | Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders - Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). | 01-13-2011 |
20110027379 | Oligo-Ethylene Glycol-Based Polymer Compositions and Methods of Use - The invention provides biodegradable PEAs, PEURs and PEUs that are synthesized by solution polycondensation to include α-amino acids and oligo-ethylene ether segments in the polymer backbone. The polymers can be obtained by substituting oligo-ethylene glycol (OEG) for aliphatic di-acid and diols during their fabrication. Also provided are compositions in which bioactive agents are dispersed in the polymers. The compositions biodegrade by enzymatic action to release incorporated bioactive agents and oligo-ethylene glycol segments, which are fully biodegradable at a molecular weight less than 400 Da. Due to their comparatively rapid surface enzymatic hydrolysis, the compositions can be used to deliver bioactive agents in a controlled manner within a relatively rapid delivery time, such as about 18 to 24 hours. | 02-03-2011 |
20110033553 | Embolization - A composition includes a plurality of particles. At least some of the plurality of particles include cross-linked polyvinyl alcohol and have a diameter of about 500 microns or less. The particles have a first average pore size in an interior region, and a second average pore size at a surface region. The first average pore size being greater than the second average pore size. The composition also includes a carrier fluid. The plurality of particles being in the carrier fluid. | 02-10-2011 |
20110052717 | SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLES - Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insoluble peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dl/g, as measured in chloroform at 25° C. and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows: D (v,0.1) is between 10 and 30 micrometers, D (v,0.5) is between 30 and 70 micrometers, D (v,0.9) is between 50 and 1 10 micrometers. | 03-03-2011 |
20110064820 | Pharmaceutical Compositions Comprising Phosphate-Binding Polymer - The present invention discloses pharmaceutical composition comprising phosphate binding polymers such as Sevelamer carbonate substantially free of monovalent anion other than bicarbonate anion. Particularly, monovalent anion content is less than about 0.05% (w/w). Disclosed are compositions comprising wet granulated Sevelamer carbonate free of added metal ions and/or added monovalent anion source. | 03-17-2011 |
20110064821 | ENCAPSULATION OF BIOLOGICALLY ACTIVE AGENTS - The present invention provides methods of encapsulating biologically active agents such as proteins in particulate carriers such as nanoparticles. Also provided are methods of delivery of proteins across the blood brain barrier in nanoparticles, and uses of such compositions in treatment. | 03-17-2011 |
20110081422 | PROLONGED RELEASE OF LOCAL ANESTHETICS USING MICROPARTICLES AND SURGERY APPLICATIONS - Methods and compositions for providing long term pain relief in, for example, surgery recovery, including injecting a composition comprising a plurality of microparticles having different sizes and at least one local anesthetic loaded into the microparticles at different loading levels. Extended prolonged blockage of nerve action in sheep testing was confirmed. Some of the microparticles comprise a high loading of local anesthetic. Testing in sheep showed nerve blockage for at least six days. | 04-07-2011 |
20110091566 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS - The present application discloses a sustained release composition in pellet form, wherein the core of the pellet comprises: (a) a therapeutically effective amount of a medicament; (b) 0.5 to 50% by weight of a water-soluble polymer; and (c) 25% by weight of a water-insoluble polymer applied as an aqueous latex dispersion and subsequently the water is removed, wherein the sum of the percentages of the medicament, the water-insoluble polymer and the water-soluble polymer is equal to or less than 100%. It also discloses methods of making this composition. | 04-21-2011 |
20110097419 | Poly(Propargyl-L-Glutamate) and Derivatives Thereof - A process of the present invention is directed toward conducting highly selective, high yield post-polymerization reactions on polypeptides to prepare functionalized polypeptides. In certain embodiments, the polypeptides can be prepared by ring opening polymerization of N-carboxyanhydrides. In certain embodiments, the post-polymerization reaction is a “click chemistry” reaction. In certain embodiment, the “click chemistry” reaction is a triazole-forming reaction involving an alkyne on the polypeptide and an azide. | 04-28-2011 |
20110097420 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME - Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component comprising a polymerizable resin comprising ethylenic unsaturated double bond, a second component comprising a compound comprising more than one type of amine selected from the group consisting of primary amines, secondary amines, tertiary amines and quaternary amines, and, optionally, the cement product includes a bioactive component to promote bone formation. | 04-28-2011 |
20110135744 | Nanoparticle Based Therapy for Dispersing Mucin - There are provided compositions and methods to disperse mucin and/or actin using nanoparticles wherein the average diameter of the nanoparticles is less than about 1000 nm. | 06-09-2011 |
20110142951 | MICELLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS - Composition comprising a polymeric micelle and an associated polynucleotide. | 06-16-2011 |
20110142952 | Pharmaceutical Compositions - This invention relates to crosslinked amine-containing polymers for binding compounds or ions, and more specifically relates to pharmaceutically acceptable compositions for binding compounds or ions that include crosslinked amine-containing polymers. The pharmaceutically acceptable composition includes, for example, crosslinked polyamine particles, or pharmaceutically acceptable salts thereof, having a particle size distribution wherein greater than 10 vol. % of the particles have a particle size greater than 500 μm. | 06-16-2011 |
20110151015 | IMMUNOMODULATOR PARTICLES AND METHODS OF TREATING - A method of stimulating an immune response in a subject including administering a micrometer-sized particle coupled with an antigen to the subject, wherein increasing the aspect ratio of the micrometer-sized particle increases the immune response. A method of stimulating an immune response in a subject including administering to the subject a plurality of particles, wherein each particle is coupled with an immuno stimulating agent and a protein. A vaccine particle composition including a plurality of particles configured to release a first protein at a first rate and a second protein at a second rate and configured to provide priming and boosting capability in a single dose. | 06-23-2011 |
20110206773 | SUSTAINED DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES - Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents such as AG1478 to induce nerve regeneration, specifically regeneration of the optic nerve useful for managing elevated intraocular pressure (TOP) in the eye. | 08-25-2011 |
20110280948 | COMPOSITIONS AND METHODS FOR SEPARATING, CHARACTERIZING AND ADMINISTERING SOLUBLE SELENOGLYCOPROTEINS - The invention relates to soluble selenium compositions and methods of production, separation and purification thereof. In particular the present invention provides methods of preparing water soluble selenoglycoproteins (e.g., via extracting selenoglycoproteins from selenium enriched yeast), methods of supplementing a selenium deficient composition via admixing water soluble selenoglycoproteins with the selenium deficient composition, compositions comprising the water soluble selenoglycoproteins and methods of administering the same. | 11-17-2011 |
20110280949 | MICROPARTICLES FOR USE IN IMMUNOGENIC COMPOSITIONS - Immunogenic compositions are disclosed which comprise microparticles that comprise a biodegradable polymer, an immunological adjuvant and a tocol-family compound. Methods of making and using such microparticle compositions are also disclosed. | 11-17-2011 |
20110287105 | Composition comprising biodegradable polymers for use in a cosmetic composition - The present invention relates to certain novel polymer powder compositions suitable for personal care and cosmetic compositions. The present invention also relates to cosmetic compositions comprising such novel polymer powders. The present invention also relates to processes for manufacturing the polymer powders, methods of making cosmetic and personal care compositions and the use of such cosmetic compositions in topical applications. | 11-24-2011 |
20120003322 | PH-SENSITIVE DENDRITIC POLYMERIC MICELLES - The present invention relates to a pH-sensitive PIC (polyion complex) type polymeric micelle formed by electrostatic interaction between a dendritic block copolymer and another polymer of opposite charge. The presence of a dendritic block copolymer confers high stability to the micelles in physiological conditions, while in the acid medium of tumor tissues (pH 6.5) or cell compartments, such as the endosome/lysosome (pH 5.0-5.5), the micelles tend to become destabilized, being able to selectively release drugs or macromolecules encapsulated therein. The micelles are characterized by high stability against ionic strength, dilution and temperature. They can further be lyophilized and conserved in solid state. | 01-05-2012 |
20120040011 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS - 1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate. | 02-16-2012 |
20120082733 | METHODS FOR PROCESSING MICROSPHERES, MICROSPHERES PROCESSED THEREBY, AND USES THEREOF - The invention provides a manufacturing method for processing polymeric microspheres which are suspended in a liquid. The invention also provides polymeric microspheres produced by the method which can be used in medical settings as tissue fillers, tissue bulking agents, embolization agents, and/or as drug delivery agents. | 04-05-2012 |
20120107408 | PHARMACEUTICAL MICROPARTICLES - Microparticles consisting of (a) a matrix with a mixture of (a1) at least one hydrophobic, biologically degradable polymer and (a2) optionally at least one water-soluble polymer, (b) a pharmaceutical active ingredient distributed in the matrix, and (c) in addition at least one water-insoluble, surface-active substance from the group of lecithins and phospholipids, distributed in the matrix, and a three-phase emulsion process for their preparation. | 05-03-2012 |
20120128783 | Compositions and methods for delivery of frozen particle adhesives - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-24-2012 |
20120237606 | HOLLOW PARTICULATE BODY - A particulate body having a hollow particle and a surface polymer disposed on the outside of the hollow particle and suitable for use in solid phase synthesis, especially production of peptides and oligonucleotides. The particulate body may be used as a chromatography stationary phase column and the buoyancy of the body allows the column to be packed efficiently from the bottom reducing the risk of damage to the stationary phase. The buoyancy of the particulate body may also allow species for example a catalyst to be suspended in a liquid phase to allow reactions, for example hydrolysis of vegetable oil and esterification to produce biodiesel to be carried out with a reduced risk of catalyst loss from a reaction zone. | 09-20-2012 |
20120276211 | POLYMERIZABLE LACTAMIC COPOLYMERS SUITABLE FOR THE FORMATION OF COATINGS ON MICROENCAPSULATED PARTICLES - This present application relates to microcapsules or compositions containing microcapsules wherein the microcapsules comprise a polymerizable lactamic copolymer. More particularly, certain aspects are directed to the use of polymerizable lactamic copolymers in the formation of coatings on microencapsulated particles. These polymerizable lactamic copolymers can result in surface modified microencapsulated particles that may be anionic, non-ionic, or cationic. | 11-01-2012 |
20130071484 | Self-Assembled Toroidal-Spiral Particles and Manufacture and Uses Thereof - Toroidal-spiral shaped particles, their method of manufacture, and uses thereof are disclosed. The toroidal-spiral particles can contain at least one active agent, such as a drug, and provide a controlled, sustained release of the active agent. | 03-21-2013 |
20130171261 | Process for Preparing Cyclic Esters Comprising Unsaturated Functional groups And Polyesters Prepared From Same - Disclosed herein are process for preparing cyclic esters comprising unsaturated functional groups. Also disclosed are copolymers prepared from the cyclic esters. The copolymers can be used to form microparticles, polymer micelles, etc., which are useful in drug delivery applications. | 07-04-2013 |
20130209570 | DRUG DELIVERY SYSTEMS AND USE THEREOF - The invention provides a microsphere formulation for the sustained delivery of an aptamer, for example, an anti-Vascular Endothelial Growth Factor aptamer, to a preselected locus in a mammal, such as the eye. In addition, the invention provides methods for making such formulations, and methods of using such formulations to deliver an aptamer to a preselected locus in a mammal. In particular, the invention provides a method for delivering the aptamer to an eye for the treatment of an ocular disorder, for example, age-related macular degeneration. | 08-15-2013 |
20130251816 | CANCER CELL TARGETING USING NANOPARTICLES - The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries. | 09-26-2013 |
20130251817 | CANCER CELL TARGETING USING NANOPARTICLES - The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries. | 09-26-2013 |
20130280338 | TAMPER RESISTANT AND DOSE-DUMPING RESISTANT PHARMACEUTICAL DOSAGE FORM - A tamper-resistant pharmaceutical dosage form comprising a pharmacologically active ingredient embedded in a prolonged release matrix, which comprises a prolonged release matrix material selected from the group consisting of nonionic acrylic polymers and waxy materials and which provides prolonged release of the pharmacologically active ingredient, resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol. | 10-24-2013 |
20130280339 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic)acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles. | 10-24-2013 |
20130287857 | Vaccine Nanotechnology - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at last one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof. | 10-31-2013 |
20130295191 | Stable Formulations for Lyophilizing Therapeutic Particles - The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles. | 11-07-2013 |
20130302431 | Polymorph Compositions, Methods of Making, and Uses Thereof - The described invention provides a biodegradable, biocompatible delivery system of flowable sustained release microparticulate composition of a substantially pure crystalline form of a bioactive agent such as, for example, nimodipine, a process of preparing a therapeutic form of a substantially pure crystalline form of the bioactive agent and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury. | 11-14-2013 |
20130302432 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles. | 11-14-2013 |
20130302433 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. | 11-14-2013 |
20130309314 | COMPOSITIONS OF ROTIGOTINE, DERIVATIVES THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS OF ROTIGOTINE OR ITS DERIVATIVE - The disclosure provides a composition comprising rotigotine or a pharmaceutically acceptable salt thereof; at least one poly(lactide-co-glycolide) (PLGA); and at least one fatty acid, wherein the at least one fatty acid is at least 0.5% in weight relative to the total weight of the composition. The composition as disclosed herein has significantly reduced burse release effect. The disclosure also provides a method of treating Parkinson's disease comprising administering an effective amount of the composition as disclosed to a subject in need thereof. | 11-21-2013 |
20130316010 | POLYMERIC MICROPARTICLES - A pharmaceutical composition is provided comprising microparticles encapsulating high weight percent active agent and providing sustained release over a prolonged period of time of active agent levels bioequivalent to direct administration of active agent. Polymeric microparticle compositions containing one or more active agents, and methods of making and using thereof, are described. The microparticles are optimized for the agent to be delivered, so that the hydrophobicity or hydrophilicity of the polymer and charge of the polymer maximizes loading of the agent, and the selection and molecular weight of the polymers maximize release of an effective amount of the active agent for the desired period of time. | 11-28-2013 |
20130323319 | MODIFIED IMMUNE-MODULATING PARTICLES - The current invention involves the surprising finding that when carboxylated particles, such as carboxylated polystyrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles. | 12-05-2013 |
20130337077 | NANOSPHERES FOR THERAPEUTIC AGENT DELIVERY - Provided is a nanosphere for delivery of a therapeutic agent comprising: a polymer matrix; discrete liquid oil droplets dispersed in the polymer matrix; and a therapeutic agent dissolved or dispersed in the oil. In some embodiments, the nanosphere is pegylated. In some embodiments, the nanosphere has a diameter of from about 100 nm to about 300 nm. In further preferred embodiments, the nanosphere has a diameter of from about 150 nm to about 250 nm. In yet further embodiments, the nanosphere has a diameter of from about 180 nm to about 220 nm. In some embodiments, the oil comprises a lipid or a phospholipid. In further embodiments, the lipid or the phospholipid has a melting point below 20° C. In some embodiments, the polymer is a natural, modified or synthetic polymer. In further embodiments, the polymer is biodegradable. | 12-19-2013 |
20130337078 | PARTICULATE CONSTRUCTS FOR RELEASE OF ACTIVE AGENTS - Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments. | 12-19-2013 |
20130344158 | Therapeutic Polymeric Nanoparticles with mTOR Inhibitors and Methods of Making and Using Same - The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer. | 12-26-2013 |
20130344159 | IMPLANTABLE SWELLABLE BIO-RESORBABLE POLYMER - The present invention relates to a polymer obtained from the polymerization of: (i) at least one monomer of formula (I) (CH | 12-26-2013 |
20130344160 | IMPLANTABLE BIO-RESORBABLE POLYMER CHARGED WITH FRAGILE MACROMOLECULES - The present invention relates to a macromolecule-loaded bioresorbable crosslinked polymer wherein the polymer is obtainable from the polymerization of: (i) at least one monomer of formula (I) (CH | 12-26-2013 |
20140030350 | Drug Delivery Systems - The present invention relates to microparticles comprising a gel body, wherein the gel body comprises a synthetic polymer and a drug, wherein the microparticles have an average diameter in the range 40 to 1500 μm, wherein the polymer is cross-linked by groups comprising disulfide linkages and is in the form of a hydrogel. | 01-30-2014 |
20140030351 | Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weight Copolymers - The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles. | 01-30-2014 |
20140030352 | NANODISPERSION - The present invention provides a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more taxane derivative, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or its derivatives or its salts. | 01-30-2014 |
20140037749 | Delivery Scaffolds and Related Methods of Use - The present invention relates to delivery systems. In particular, the present invention provides microporous scaffolds having thereon agents (e.g., extracellular matrix proteins, exendin-4) and biological material (e.g., pancreatic islet cells). In some embodiments, the scaffolds are used for transplanting biological material into a subject. In some embodiments, the scaffolds are used in the treatment of diseases (e.g., type 1 diabetes), and related methods (e.g., diagnostic methods, research methods, drug screening). | 02-06-2014 |
20140050799 | RISPERIDONE SUSTAINED RELEASE MICROSPHERE COMPOSITION - A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage. | 02-20-2014 |
20140065234 | POLYMERSOMES, LIPOSOMES, AND OTHER SPECIES ASSOCIATED WITH FLUIDIC DROPLETS - The present invention relates generally to vesicles such as liposomes, colloidosomes, and polymersomes, as well as techniques for making and using such vesicles. In some cases, the vesicles may be at least partially biocompatible and/or biodegradable. The vesicles may be formed, according to one aspect, by forming a multiple emulsion comprising a first droplet surrounded by a second droplet, which in turn is surrounded by a third fluid, where the second droplet comprises lipids and/or polymers, and removing fluid from the second droplet, e.g., through evaporation or diffusion, until a vesicle is formed. In certain aspects, the size of the vesicle may be controlled, e.g., through osmolarity, and in certain embodiments, the vesicle may be ruptured through a change in osmolarity. In some cases, the vesicle may contain other species, such as fluorescent molecules, microparticles, pharmaceutical agents, etc., which may be released upon rupture. Yet other aspects of the invention are generally directed to methods of making such vesicles, kits involving such vesicles, or the like. | 03-06-2014 |
20140099382 | TREATMENT USING DANTROLENE - Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease. | 04-10-2014 |
20140120170 | PARTICLES COMPRISING POLYESTERAMIDE COPOLYMERS FOR DRUG DELIVERY - The present invention relates to micro- or nanoparticles comprising a polyesteramide (PEA) having a chemical formula described by structural formula (IV), Formula (IV) wherein —m+p varies from 0.9-0.1 and q varies from 0.1 to 0.9 —m+p+q=1 whereby m or p could be 0-n is about 5 to about 300; (pref 50-200) —R | 05-01-2014 |
20140127311 | BIO-COMPATIBLE NANO-POLYMER PARTICLES COMPRISING ACTIVE INGREDIENTS FOR PULMONARY APPLICATION - The present invention provides biocompatible nano-polymer particles which are composed of a biocompatible polymer, a stabilizer and an active agent for the treatment of pulmonary hypertension or erectile dysfunction and which can be used to produce a pharmaceutical preparation for the treatment of pulmonary hypertension or erectile dysfunction. Biocompatible nano-polymer particles of this invention have a diameter ranging from 10 nm to 10 μm auf, a stabilizing layer thickness between 0 and 50 nm, contain between 0 and 50% of an active agent for the treatment of pulmonary hypertension or erectile dysfunction, are nebulizable and continuously release the active agent over a period of up to 48 hours. Biocompatible nano-polymer particles of this invention can be synthesized for example using the emulsion technique known to the expert with subsequent solvent evaporation or via spray drying. | 05-08-2014 |
20140147510 | MULTIPHASIC POLYMERIC PARTICLES CAPABLE OF SHAPE-SHIFTING VIA ENVIRONMENTAL STIMULATION - Provided herein are methods of making and controlling multiphasic polymeric micro-components capable of shape-shifting. Such a multiphasic micro-component comprises a first phase (that can include a first polymer) and at least one additional phase distinct from said first phase (that can include a second polymer). One or more of the first phase and additional phase comprises a component that is responsive to an external stimulus. Thus, the micro-component exhibits a substantial physical deformation in response to: (i) the presence of the external stimulus or (ii) a change in the external stimulus. Exemplary external stimuli include temperature, pressure, light, pH, ionic strength, hydrophobicity/hydrophilicity, solvent, concentration, a stimulator chemical, sonic energy, electric energy, pressure, magnetic fields, and combinations thereof. | 05-29-2014 |
20140170229 | POLYMERIC NANOPARTICLES FOR PHOTOSENSITIZERS - Biodegradable polymeric nanoparticles comprising an inner core formed of a photodynamic agent capable of being activated to generate cytotoxic singlet oxygen are prepared. These nanoparticles have anti-cell proliferation activity and are useful in treating both cancerous and non-cancerous conditions including actinic keratosis, psoriasis and acne vulgaris. Preferably, the photodynamic agent is a hypocrellin B derivative while the polymeric nanoparticle comprises polyglycolic acid, polylactic acid or poly(lactide-co-glycolide). Hypocrellin-comprising nanoparticles are demonstrated to be activated by light or hydrogen peroxide. | 06-19-2014 |
20140186452 | Process for Preparing Therapeutic Nanoparticles - The present disclosure generally relates to a process for preparing therapeutic nanoparticles, where the process includes combining a therapeutic agent with an organic acid. The therapeutic nanoparticles may have, for example, improved drug loading and/or drug release properties. | 07-03-2014 |
20140186453 | Therapeutic Polymeric Nanoparticles with mTOR Inhibitors and Methods of Making and Using Same - The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer. | 07-03-2014 |
20140193510 | Polymer-Agent Conjugates, Particles, Compositions, and Related Methods of Use - Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles. | 07-10-2014 |
20140248368 | POWDERY EMULSIFYING COMPOSITION OF ALKYL POLYGLYCOSIDES, USE THEREOF FOR PREPARING COSMETIC EMULSIONS, AND METHOD FOR PREPARING SAME - A powdery composition C1 contains for 100% of the mass: 5 to 70 mass % and more particularly 10 to 50 mass % of at least one compound of formula (I): R—O-(G) | 09-04-2014 |
20140271903 | USE OF THERMO-SENSITIVE GEL FOR CONTROLLED DELIVERY OF ALK-5 INHIBITORS TO THE EYE AND RELATED METHODS - The present invention relates to a methods for extending the period of filtering bleb survival and/or providing for long term bleb survival following Glaucoma Filtration Surgery by delivering an ALK-5 inhibitor to a wound area (the surgical site) of a patient's eye. More particularly, the present invention relates to a method for the controlled delivery of an ALK-5 inhibitor to patient's eye using a thermo-sensitive polymer formulation, wherein the ALK-5 inhibitor is first contained in the polymer formulation at a temperature sufficient to maintain the formulation as a liquid and then applied to the eye wound opening, wherein the formulation turns to a gel. The use of the thermo-sensitive gel with ALK-5 inhibitor contained therein, provides for longer term bleb survival following Glaucoma Filtration Surgery (GFS) on a patient's eye. Thus, the present invention is particularly effective in inhibiting ocular fibrotic wound response following GFS. | 09-18-2014 |
20140294986 | Microsphere Drug Delivery System for Sustained Intraocular Release - Disclosed are biodegradable microspheres between 40 μm and 200 μm in diameter that are effectively retained in the anterior chamber of the eye without producing hyperemia. The microspheres generally contain a drug effective for the treatment of an ocular condition and include a biodegradable polymer matrix that can provide for the sustained (>7 day) release of the drug following administration to the anterior chamber of the eye. Methods for making and using the microspheres to treat an ocular condition are also disclosed. | 10-02-2014 |
20140302159 | Cosmetic composition comprising a superabsorbent polymer and a lamellar or platelet-shaped matting mineral filler - The present invention relates to a composition for topical application, comprising at least one aqueous phase, at least one superabsorbent polymer and at least one lamellar or platelet-shaped matting mineral filler. A subject of the invention is also a cosmetic treatment process for keratin materials, which consists in applying to the keratin materials a composition as defined above, and also the use of this composition in the cosmetic or dermatological field, and in particular for caring for, protecting and/or making up bodily or facial skin, or for haircare. The composition according to the invention has both a matt appearance throughout all the steps of its use, from the appearance of the product up to the finished skin, and a comfortable sensation throughout its use, from the application to the total penetration of the product. | 10-09-2014 |
20140308363 | DRUG LOADED POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles. | 10-16-2014 |
20140314865 | Vaccine Nanotechnology - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at last one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof. | 10-23-2014 |
20140314866 | MATERIALS AND METHODS FOR MODULATING IMMUNE RESPONSES - The present invention provides nanoparticle-coupled tolerogenic Treg cell therapy for treatment of immune and/or autoimmune disorders. In certain specific embodiments, the present invention can be used in the prevention and/or treatment of autoimmune diseases including, but not limited to, type 1 diabetes, lupus erythematosus (SLE), multiple sclerosis (MS), inflammatory bowel disease (IBD), rheumatoid arthritis, oophoritis, and autoimmune pathology associated with Graft versus Host Disease (GvHD) following hematopoietic stem cell transplantation. | 10-23-2014 |
20140314867 | VITAMIN K2 MICROSPHERES - A vitamin K | 10-23-2014 |
20140314868 | PROSTAGLANDIN AND PROSTAMIDE DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF - Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma. | 10-23-2014 |
20140328937 | Drug Delivery Systems and Use Thereof - The invention provides a microsphere formulation for the sustained delivery of an aptamer, for example, an anti-Vascular Endothelial Growth Factor aptamer, to a preselected locus in a mammal, such as the eye. In addition, the invention provides methods for making such formulations, and methods of using such formulations to deliver an aptamer to a preselected locus in a mammal. In particular, the invention provides a method for delivering the aptamer to an eye for the treatment of an ocular disorder, for example, age-related macular degeneration. | 11-06-2014 |
20140335193 | CONTROLLED-RELEASE INJECTABLE MICROPARTICLE - The invention relates to a controlled-release injectable microparticle comprising a polyvinyl alcohol polymer and one or more hormones, in particular progesterone. Said microparticle induces estrus in female mammals after a single application. The invention also relates to a method for obtaining the microparticle. | 11-13-2014 |
20140335194 | POLYMERIC NANOPARTICLE SOLUTION COMPOSITION AND ITS MANUFACTURING PROCESS - Disclosed are a polymeric drug carrier-containing pharmaceutical composition with enhanced stability in its solution state and a method for stabilizing the same. More particularly, disclosed are a pharmaceutical aqueous solution composition for storage under refrigeration containing a polymeric drug carrier comprising an amphiphilic block copolymer comprised of a hydrophilic block and a hydrophobic block, and a polylactic acid derivative fixed with a di- or tri-valent metal ion at its terminal carboxyl group and having preservation stability for at least 6 months, preferably at least 12 months when stored under refrigeration, and a method for stabilizing the same. | 11-13-2014 |
20140348936 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMOPLASTIC POLYURETHANES - Gastroretentive controlled release vehicles may, in some embodiments, (1) comprise a polymeric matrix and agents for the treatment, prevention, and/or mitigation of a disease and/or side effect thereof and (2) have both gastroretentive properties and controlled release properties. Preferrably, the polymeric matrix may comprise ethylene copolymers, ethyl celluloses, and/or thermoplastic polyurethanes that may optionally be partially crosslinked. | 11-27-2014 |
20140348937 | MICROCAPSULES - A composition is provided, comprising microcapsules, wherein said microcapsules comprise a core and an outer shell, wherein said core comprises one or more water-insoluble compound having melting point above 15° C., wherein said outer shell comprises one or more amino resin that is a reaction product of reactants comprising one or more polyamine and formaldehyde, and wherein said composition further comprises one or more formaldehyde scavenger, one or more reaction product of said amino resin with a formaldehyde scavenger, or a mixture thereof. Also provided is a method of making such a composition. | 11-27-2014 |
20140356444 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. | 12-04-2014 |
20140356445 | Artificial Cell Constructs For Cellular Manipulation - The present invention contemplates induction of immunological tolerance thereby providing permanent allograft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive agents which can increase the risk of infection, autoimmunity, and cancer. Immunological tolerance is thought to be mediated by regulatory T lymphocytes (T | 12-04-2014 |
20140370114 | HOMOPOLYMER NANOPARTICLES BY SELF-EMULSION POLYMERIZATION REACTION AND PREPARATION METHOD THEREOF - Disclosed herein is a preparation method of homopolymer nanoparticles without using a surfactant. The homopolymer nanoparticles prepared thereby are expected to be widely used not only as a template of a semiconductor metal oxide, a drug delivery system (DDS), an electron transport layer (ETL), and a seed having vertical structural shape, but also in a high precision field such as replacement of an organic device polystyrene bead film. | 12-18-2014 |
20140377369 | COMPOSITIONS OF ROTIGOTINE, DERIVATIVES THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS OF ROTIGOTINE OR ITS DERIVATIVES - The disclosure relates to a composition comprising rotigotine or a pharmaceutically acceptable salt thereof; at least one poly(lactide-co-glycolide) (PLGA); and at least one fatty acid, wherein the at least one fatty acid is at least 0.5% in weight relative to the total weight of the composition. The composition as disclosed herein has significantly reduced burse release effect. The disclosure also provides a method of treating Parkinson's disease comprising administering an effective amount of the composition as disclosed to a subject in need thereof. | 12-25-2014 |
20150017250 | TAMPER-RESISTANT DOSAGE FORM CONTAINING ETHYLENE-VINYL ACETATE POLYMER - The invention relates to a tamper-resistant, oral pharmaceutical dosage form comprising a pharmacologically active ingredient having psychotropic action and an ethylene-vinyl acetate (EVA) polymer which provides resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol. | 01-15-2015 |
20150017251 | MICROPARTICLES FOR USE IN IMMUNOGENIC COMPOSITIONS - Immunogenic compositions are disclosed which comprise microparticles that comprise a biodegradable polymer, an immunological adjuvant and a tocol-family compound. Methods of making and using such microparticle compositions are also disclosed. | 01-15-2015 |
20150024061 | ALLOPLASTIC INJECTABLE DERMAL FILLER AND METHODS OF USE THEREOF - A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided. In an embodiment of the method of augmenting soft tissue, the stimulation of collagen production is effected by injecting into the deep reticular dermis an a dermal filler, said dermal filler being an alloplastic injectable suspension and comprising a biocompatible and pliable material and a physiologically acceptable suspending agent. | 01-22-2015 |
20150030686 | SELF-ASSEMBLED TOROIDAL-SPIRAL PARTICLES AND MANUFACTURE AND USES THEREOF - Toroidal-spiral shaped particles, their method of manufacture, and uses thereof are disclosed. The toroidal-spiral particles can contain at least one active agent, such as a drug, and provide a controlled, sustained release of the active agent. | 01-29-2015 |
20150037428 | GEOMETRICALLY ENGINEERED PARTICLES AND METHODS FOR MODULATING MACROPHAGE OR IMMUNE RESPONSES - Disclosed herein are geometrically engineered particles having varied shapes and sizes and surface charge which can incorporate drugs and/or other biomaterials for targeted delivery, such as pulmonary delivery. The size, shape, etc. of a particle can be designed and corresponding particles can be prepared that target or de-target immunological responses to the particles themselves, for example, the response of alveolar macrophages. Methods of modulating immune responses by utilizing the particles are also disclosed. The particles can be composed substantially of therapeutic, drug and polymer or can comprise polymers and proteins. The particles may also be composed of diagnostic agents and additional biomaterials to confer aerosolization and cellular uptake properties. The particles also may have a range of physical features such as fenestrations, angled arms, asymmetry and surface roughness, charge which alter the interactions with cells and tissues. | 02-05-2015 |
20150037429 | Controlled Release Microparticles - Formulations for controlled, sustained release of biologically active agents for the treatment of ocular disorders have been developed. These formulations are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof. The microparticles are characterized by low burst levels and efficient drug loading and sustained release. | 02-05-2015 |
20150044296 | COMBINATION THERAPY TO IMPROVE JOINT, TENDON, AND LIGAMENT HEALING - The present invention is directed to kit, drug combinations and methods for promoting endogenous bone marrow (BM)-derived vasculogenic progenitor cell (PC) mobilization, sensitization of such cells and chemotaxis to sites of joint injury or disease. One embodiment of the present invention, directed to a method of promoting joint complex healing, comprises the step of administering an effective amount of a bone marrow (BM) derived vasculogenic progenitor cell mobilization factor to an animal or human exhibiting joint injury or joint disease. The method further comprises the step of administering, concurrently to the mobilization factor, an effective amount of a progenitor cell sensitizing factor to mobilize progenitor cells and sensitize the progenitor cells to one or more chemotactic agents present at the site of joint injury or joint disease. | 02-12-2015 |
20150050357 | NANOPARTICLE ISOFLAVONE COMPOSITIONS & METHODS OF MAKING AND USING THE SAME - The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein. | 02-19-2015 |
20150064268 | NANOPARTICLES FOR STIMULATING ELASTOGENESIS - Elastogenic nanoparticles including a polymeric core having a surface that is functionalized with a cationic amphiphilic compound, and comprising an active agent having pro-elastogenic and/or anti-proteolytic activity, are described herein. The elastogenic nanoparticles can be used in method of stimulating elastogenesis in a subject by administering to the subject a therapeutically effective amount of elastogenic nanoparticles. | 03-05-2015 |
20150093444 | BLOCK COPOLYMER, LIQUID COMPOSITE THEREOF, NUCLEIC ACID PREPARATION, PREPARATION METHODS THEREFOR, AND USE THEREOF - Provided are a polycaprolactone-polyphosphate block copolymer, a liquid composite formed by the block copolymer, a nucleic acid preparation, preparation methods for the copolymer and the liquid composite, and the use of the copolymer and the liquid composite in a nucleic acid medicine delivery system. The block copolymer prepared using the present invention has good biocompatibility, low cytotoxicity, and good biodegradability. The micelles provided in the present invention self-assemble into nano-particles in an aqueous solution, and have good stability, biocompatibility, and biodegradability, and low cytotoxicity. The preparation method is simple, has high repeatability, as a vector can protect small nucleic acids such as siRNA from biodegradation, can combine with the scale effect of nano-particles, and can be used for treating different diseases. Additionally, bonding targeting groups enable specificity recognition of different cancer cells. | 04-02-2015 |
20150110886 | POTASSIUM-BINDING AGENTS FOR TREATING HYPERTENSION AND HYPERKALEMIA - The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function. | 04-23-2015 |
20150118320 | AQUEOUS DISPERSION COMPRISING SILICONE ELASTOMER PARTICLES, A SILICONE ELASTOMER PARTICLE AND A COSMETIC - One of the purposes of the present invention is to provide an aqueous dispersion of silicone elastomer particles to provide a stable emulsion and the silicone elastomer particle, wherein a polyoxyethylene alkyl ether which has an alkyl group having a large number of carbon atoms is used as a surfactant. Further, another purpose is to provide a cosmetic comprising said aqueous dispersion or said silicone elastomer particles and giving a good feeling in the use. The present invention provides an aqueous dispersion comprising (A) silicone elastomer particles having a 90% volume cumulative diameter (D90) of 0.3 to 20 μm in an amount of 5 to 80 mass %, based on a total mass of the aqueous dispersion, (B) at least one polyoxyethylene alkyl ether having an alkyl group having 18 carbon atoms in an amount of 0.01 to 15 mass %, based on a total mass of the aqueous dispersion, wherein a hydrophile-lipophile balance (HLB) of the polyoxyethylene alkyl ether is 12.8 to 15.1, and (C) water in an amount of 19 to 94 mass %, based on a total mass of the aqueous dispersion. Further, the present invention provides a material comprising the aforesaid components (A) and (B), a method for preparing the material and a cosmetic comprising the aqueous dispersion or the material. | 04-30-2015 |
20150132399 | COMPOSITION AND METHOD FOR SULFATED NON-ANTICOAGULANT LOW MOLECULAR WEIGHT HEPARINS IN CANCER AND TUMOR METASTASIS - A nanoformulation that includes nanoparticles. Each nanoparticle includes a shell in which a glycosaminoglycan (GAG is encapsulated. The GAG is ionically or covalently bonded to the shell. The GAG is selected from the group consisting of sulfated non-anticoagulant heparin (SNACH), super-sulfated non-anticoagulant heparin (S-SNACH), and a combination thereof. The shell includes Poly (lactic-co-glycolic acid) (PLGA), Polyethylene Glycol (PEG)-PLGA, maleimide-PEG-PLGA, chitosan, chitosan-PLGA, methoxy-polyethyleneglycol-poly (lactide-co-glycolide) (MPEG-PLGA)-(maleimide-PEG-PLGA), PLGA-Polycaprolate, or calcium alginate. A method of using the nanoformulation to treat a cancer in a subject includes administering to the patient a therapeutically effective amount of the nanoformulation for treating the cancer. | 05-14-2015 |
20150140111 | PREPARATIONS OF EFFERVESCENT FORMULATIONS COMPRISING SECOND AND THIRD GENERATION CEPHALOSPORIN AND USES THEREOF - The invention relates to effervescent pharmaceutical dosage forms including cefdinir as the active agent, and their preparation. The invention also relates to effervescent formulations including ceftibuten and/or its pharmaceutically acceptable salts, hydrates, solvates, esters, amorphous and crystal forms and/or a combination thereof. The invention also relates to pharmaceutical compositions including (Z)-3-Carboxymethyl-7-(2-(2-furyl)-2-methoxyiminoacetylamino)-3-sefem-4-carboxylic acid which is named cefuroxime axetil or any pharmaceutically acceptable derivative thereof, and the use of these compositions in the treatment of bacterial infections. Lastly, the invention relates to pharmaceutical formulations including a third generation cephalosporin together with clavulanic acid and/or derivatives thereof as the active agents. | 05-21-2015 |
20150147406 | Intraocular Formulation - Biodegradable therapeutic agent incorporating microspheres formulated in a high viscosity carrier suitable for intraocular administration to treat an ocular condition. The formulation can also be used to treat non-ocular conditions such as articular pathologies | 05-28-2015 |
20150290136 | PROCESS FOR PREPARING A GRANULATED PRODUCT FROM A POWDER COMPOSITION - The invention discloses a process for preparing granulated product from a powder composition comprising the mixed components (a) and (b) and (c) or (d) or both, with (a), a copolymer consisting of free-radical-polymerized C1- to C4-esters of acrylic or methacrylic acid and alkyl(meth)acrylate monomers with tertiary amino groups in the alkyl side groups (b) 5 to 25% by weight, based on (a), of a C | 10-15-2015 |
20150320856 | CONTROLLED RELEASE OF IMMUNOSUPPRESSANTS FROM SYNTHETIC NANOCARRIERS - Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments. | 11-12-2015 |
20150342898 | COMPOSITION AND FOOD OR DRINK - Compositions contain γ-oryzanol and biocompatible particles that incorporate γ-oryzanol inside thereof. The biocompatible particle may contain polylactideglycolide copolymer with a number mean particle size of 2.5 to 1,000 nm or a polyethylene glycol modification thereof. Such compositions are used for improvement of insulin resistance. In addition, such compositions are used for treatment or prevention of diseases selected from the group consisting of obesity, dystipidemia, impaired glucose tolerance, diabetes mellitus, arteriosclerosis, and inflammatory diseases. | 12-03-2015 |
20150352145 | Method and System for Treatment of Damaged Biological Tissue - Biomaterial compositions and articles comprising extracellular matrix (ECM) and an ECM-mimicking biomaterial, such as poly(glycerol sebacate) (PGS), for treating damaged biological tissue; particularly, damaged cardiovascular tissue. The biomaterial compositions and articles can also include additional biologically active agents, such as growth factors, and polymeric materials, such as polyepsilon-caprolactone (PCL). | 12-10-2015 |
20150352146 | MULTI-COMPONENT PARTICLES FOR INJECTION AND PROCESSES FOR FORMING THE SAME - In accordance with one aspect of the invention, novel compositions containing injectable particles are provided in which the injectable particles contain at least two polymeric components that differ in composition from one another (e.g., because at least one polymeric component contains a polymer that is not present in another polymeric component). | 12-10-2015 |
20150359852 | METHODS AND COMPOSITIONS FOR BONE FORMATION - A method and system to induce bone growth by locally delivering bone morphogenetic proteins (BMPs) to the target location for a prolonged period without invasive procedures are disclosed. The new bone growth is induced by delivering cells producing BMPs from transduced viral vectors to the target cite. In various embodiments, the cells are encapsulated in hydrogel microspheres that are non-degradable or degradable by enzymes produced during the bone formation process. Various embodiments may be used to induce spinal fusion or repair critical bone defects. | 12-17-2015 |
20150374633 | THERMORESPONSIVE HYDROGEL CONTAINING POLYMER MICROPARTICLES FOR NONINVASIVE OCULAR DRUG DELIVERY - A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is sustainably released for a period of at least five days. | 12-31-2015 |
20160024241 | POLYMER NANOPARTICLES - A process for the preparation of a polymer nanoparticle by a photoinduced emulsion polymerization includes preparing an emulsion comprising at least one surfactant, a dispersed phase and a continuous phase. The dispersed phase comprises at least one polymerizable monomer and the continuous phase comprises water and at least one photoinitiator. The at least one polymerizable monomer is polymerized by exposing the emulsion to an electromagnetic radiation having a wavelength so as to induce a generation of radicals from the at least one photoinitiator. The at least one photoinitiator is selected from at least one compound of formula (I) | 01-28-2016 |
20160030348 | VACCINATION COMPOSITION - The present invention is directed to vaccination composition comprising a particle comprising a polymer matrix incorporating an adjuvant and/or an antigen, to method of making them and use. Particularly, the present invention results in adjuvants and/or antigens, covalently entrapped in or coupled to polymer carriers or polymeric devices, such as micelles, nanoparticles, microspheres and other types of polymer devices for controlled release; the adjuvant and/or antigen are covalently bonded in or to the polymer carriers or polymeric devices. | 02-04-2016 |
20160074366 | TREATMENT USING DANTROLENE - Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease. | 03-17-2016 |
20160089335 | DRUG LOADED MICROSPHERES FOR POST-OPERATIVE CHRONIC PAIN - A microsphere is disclosed. The microsphere includes at least one biodegradable polymer and at least one local anesthetic, wherein about 75% of the at least one local anesthetic is released by about 72 hours and from about 80% to about 90% of the at least one local anesthetic is released by about 120 hours, thereby relieving chronic pain for at least 28 days. | 03-31-2016 |
20160089389 | CHEMOEMBOLISATION - A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin. | 03-31-2016 |
20160095933 | WATER SOLUBLE POLYCARBONATES FOR MEDICAL APPLICATIONS - Water soluble biodegradable polymers were prepared by an organoacid catalyzed ring opening polymerization (ROP) of a cyclic carbonate monomer bearing an active ester side chain. The initial polymer comprising an active ester side chain was treated with an amino-alcohol, which transformed the active ester groups to N-substituted amide groups bearing mono-hydroxy alkyl groups and/or dihydroxy alkyl groups, thereby forming the water soluble polymers. The water-soluble polymers are non-toxic and exhibit stealth properties in buffered serum solution. | 04-07-2016 |
20160101054 | SUSTAINED DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES - Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents such as AG1478 to induce nerve regeneration, specifically regeneration of the optic nerve useful for managing elevated intraocular pressure (IOP) in the eye. | 04-14-2016 |
20160106881 | PROCESS TO MAKE WATER-ABSORBING POLYMER STRUCTURE HAVING SUPERABSORBENT POLYMER INDEX - The present invention relates to a process for the production of a water-absorbing polymer structure, comprising the process steps:
| 04-21-2016 |
20160136094 | Compositions For Treating Acute, Post-Operative, or Chronic Pain and Methods of Using the Same - Provided herein are compositions for treating acute, chronic, or post-operative pain in a subject, said compositions comprising an anticonvulsant agent and a biodegradable carrier, wherein the agent is incorporated within the biodegradable carrier. Methods of treating pain in a subject and kits for producing compositions for treating acute, chronic or post-operative pain in in a subject are also disclosed herein. | 05-19-2016 |
20160136096 | INJECTABLE DELIVERY OF MICROPARTICLES AND COMPOSITIONS THEREFOR - Compositions and methods of making and using of microparticle compositions that provide faster flow or improved injectability through smaller or small-diameter needles have been developed. Notably, the microparticle compositions can be successfully delivered or administered through smaller-diameter needles than other microparticle compositions prepared from biocompatible or biodegradable polymers including, for example, poly(lactide), poly(lactide-co-glycolide), polycaprolactone, or poly-3-hydroxybutyrate. The microparticle compositions can exhibit a higher solids loading for a given needle size and/or faster flow through needles than other microparticle compositions. Further, blending or mixing the polymer of the microparticle composition with other polymer formulations can enhance the injectability of the resulting formulation. | 05-19-2016 |
20160143844 | Drug Delivery Systems and Use Thereof - The invention provides a microsphere formulation for the sustained delivery of an aptamer, for example, an anti-Vascular Endothelial Growth Factor aptamer, to a preselected locus in a mammal, such as the eye. In addition, the invention provides methods for making such formulations, and methods of using such formulations to deliver an aptamer to a preselected locus in a mammal. In particular, the invention provides a method for delivering the aptamer to an eye for the treatment of an ocular disorder, for example, age-related macular degeneration. | 05-26-2016 |
20160151298 | DOCETAXEL POLYMERIC NANOPARTICLES AND METHODS OF TREATING CANCERS USING SAME | 06-02-2016 |
20160158364 | Menthol-based Nanoparticles for Drug Delivery - The subject invention pertains to formulations comprising poly(menthyl acrylate) nanoparticles comprising at least one active ingredient contained in a plurality of hydrophobic carriers and dispersed in an aqueous medium. The subject invention further pertains to methods of polymerization of drug loaded nanoparticles made up of methyl acrylate monomers in an aqueous emulsion. | 06-09-2016 |
20160175247 | COMPOSITION CONTAINING POLYCATIONIC TRIBLOCK COPOLYMER, POLYANIONIC POLYMER AND PHYSIOLOGICALLY ACTIVE PEPTIDE | 06-23-2016 |
20160175265 | REACTIVE OXYGEN SPECIES (ROS)-RESPONSIVE COMPOSITIONS AND METHODS THEREOF | 06-23-2016 |
20160175345 | PHARMACEUTICAL COMPOSITIONS FOR TREATING HYPERKALEMIA | 06-23-2016 |
20160193299 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | 07-07-2016 |
20160250153 | NOVEL METHODS | 09-01-2016 |
20180021260 | Artificial Cell Constructs For Cellular Manipulation | 01-25-2018 |